$120.01
0.26% yesterday
NYSE, Jun 27, 10:10 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock price

$120.01
+6.80 6.01% 1M
+21.62 21.97% 6M
+22.70 23.33% YTD
+13.46 12.63% 1Y
+39.28 48.65% 3Y
+37.34 45.16% 5Y
+26.73 28.66% 10Y
+74.90 166.05% 20Y
NYSE, Closing price Fri, Jun 27 2025
-0.31 0.26%
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Key metrics

Basic
Market capitalization
$228.8b
Enterprise Value
$252.9b
Net debt
$24.0b
Cash
$7.1b
Shares outstanding
2.0b
Valuation (TTM | estimate)
P/E
18.49 | 13.80
P/S
4.30 | 4.13
EV/Sales
4.75 | 4.56
EV/FCF
17.03
P/B
6.13
Dividends
DPS
$3.99
Yield 1Y | 5Y
3.33% | 3.72%
Growth 1Y | 5Y
6.80% | 6.44%
Payout 1Y | 3Y
63.71% | 63.27%
Increased
6 Years
Financials (TTM | estimate)
Revenue
$53.3b | $55.5b
EBITDA
$17.7b | $22.7b
EBIT
$17.4b
Net Income
$12.9b | $17.0b
Free Cash Flow
$14.8b
Growth (TTM | estimate)
Revenue
11.57% | 7.22%
EBITDA
55.37% | 37.09%
EBIT
54.29%
Net Income
-15.65% | 42.64%
Free Cash Flow
43.77%
Margin (TTM | estimate)
Gross
75.69%
EBITDA
33.18% | 40.86%
EBIT
32.73%
Net
24.15% | 30.71%
Free Cash Flow
27.88%
Financial Health
Equity Ratio
43.08%
Return on Equity
27.11%
ROCE
25.51%
ROIC
21.73%
Debt/Equity
0.81
More
EPS
$6.49
FCF per Share
$7.58
Short interest
0.20%
Employees
76.06k
Rev per Employee
$680.00k
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Novartis ADR forecast:

12x Buy
38%
16x Hold
50%
4x Sell
13%

Analyst Opinions

32 Analysts have issued a Novartis ADR forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
53,257 53,257
12% 12%
100%
- Direct Costs 12,948 12,948
3% 3%
24%
40,309 40,309
15% 15%
76%
- Selling and Administrative Expenses 12,781 12,781
3% 3%
24%
- Research and Development Expense 9,401 9,401
12% 12%
18%
17,672 17,672
55% 55%
33%
- Depreciation and Amortization 243 243
212% 212%
0%
EBIT (Operating Income) EBIT 17,429 17,429
54% 54%
33%
Net Profit 12,859 12,859
16% 16%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
GlobeNewsWire
2 days ago
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
Neutral
GlobeNewsWire
3 days ago
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.
Positive
Seeking Alpha
3 days ago
Novartis AG could be a qualitative investment with a margin of safety. The drugmaker arguably has the balanced commercial drug portfolio and drug pipeline needed to sustain growth in the years ahead. Novartis carries a very manageable debt load for a company of its size.
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today